This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Veeva Systems (VEEV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Veeva Systems (VEEV) closed at $280.63, marking a +0.54% move from the previous day.
Is Veeva Systems (VEEV) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (VEEV) Outperforming Other Computer and Technology Stocks This Year?
3 Great Growth Stocks to Buy Now at a Discount
by Benjamin Rains
All of these factors create a bullish outlook and might make some investors consider buying strong growth stocks that have yet to fully recover from mid-February's tech and growth selloff...
Why You Should Hold AngioDynamics (ANGO) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Cardinal Health (CAH), HHS Partner to Offer Pandemic Support
by Zacks Equity Research
The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.
Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials
by Zacks Equity Research
Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.
How to Find Strong Buy Computer and Technology Stocks Using the Zacks Rank
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Here's Why You Should Hold Masimo (MASI) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Neogen (NEOG) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance in both its Animal Safety and Food Safety segments during the fiscal third quarter pushes Neogen (NEOG) to a 52-week high.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool
by Zacks Equity Research
PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.
Everbridge (EVBG) Set to Acquire Software Marker xMatters
by Zacks Equity Research
Everbridge (EVBG) gears up to acquire software maker, xMatters to enhance its IT Alerting and Incident Management offerings.
BD's (BDX) $65M Investment to Boost Supply-Chain Strength
by Zacks Equity Research
BD's (BDX) $65-million investment in constructing an advanced facility will become integral to the U.S. medical device supply chain.
Here's Why You Should Retain Luminex (LMNX) Stock for Now
by Zacks Equity Research
Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.
5 Enterprise Software Stocks to Buy Amid Rise in Digital Spending
by Radhika Pujara
Here we discuss five enterprise software companies -- MSFT, ADBE, CDNS, VEEV, and UPLD -- which are well poised to gain from coronavirus crisis triggered spend on digital transformation amid proliferation of cloud computing.
5 Best Stocks With Rising P/E to Buy for Solid Returns
by Sanghamitra Saha
Forget undervalued stocks, play these top-ranked stocks with rising P/E.
Is Veeva (VEEV) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Veeva (VEEV) could produce exceptional returns because of its solid growth attributes.
Veeva (VEEV) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.
Software is the New Gold: Storing Value in the Digital-Crypto Age
by Kevin Cook
Time for the final nail in the gilded sarcophagus of the barbarous relic.
Boehringer Ingelheim Adopts Veeva's (VEEV) CRM Solution
by Zacks Equity Research
Veeva's (VEEV) CRM Engage Meeting enables Boehringer Ingelheim to host more than a million virtual meetings to stay connected with physicians.
Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)
by Zacks Equity Research
Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.
Veeva (VEEV) Application Completes Consent for First Patient (Revised)
by Zacks Equity Research
With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.
Veeva (VEEV) Application Completes Consent for First Patient
by Zacks Equity Research
With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.